Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Athersys: A Lucrative China Stem Cell Licensing Deal Seems Imminent [Seeking Alpha]

Athersys, Inc. (ATHX) 
Last athersys, inc. earnings: 11/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: athersys.com/press-releases
Company Research Source: Seeking Alpha
Athersys: A Lucrative China Stem Cell Licensing Deal Seems ImminentSummaryAthersys files 8-K extending Healios K.K.'s right of first refusal deadline by one week to December 14 for China rights to MultiStem.Webinar discussing Athersys/Healios Partnership, sponsored by Nikon Cell Innovation previously scheduled for December 12.Table is set for significant China expansion deal prior to webinar.Mesoblast $40,000,000 upfront deal with China's Tasly Pharmaceutical Group for cardiovascular alliance has set the benchmark for what to look for. Show less Read more
Impact Snapshot
Event Time:
ATHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ATHX alerts
Opt-in for
ATHX alerts

from News Quantified
Opt-in for
ATHX alerts

from News Quantified